Showing 1 - 13 results of 13 for search 'Raoul Tibes', query time: 0.05s
Refine Results
-
1
-
2
Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome by Glen J. Weiss, Raoul Tibes, Lisa Blaydorn, Gayle Jameson, Molly Downhour, Erica White, Ivor Caro, Daniel D. Von Hoff
Published 2011-12-01
Article -
3
Triazolo[4,5-d]pyrimidines as Validated General Control Nonderepressible 2 (GCN2) Protein Kinase Inhibitors Reduce Growth of Leukemia Cells by Lea Lough, Dan Sherman, Manuel Becerra-Flores, Deepika Vasudevan, Olga Lavinda, Eric Ni, Hong Wang, Hyung Don Ryoo, Raoul Tibes, Timothy Cardozo
Published 2018-01-01
Article -
4
Corrigendum to “Triazolo[4,5-d]pyrimidines as validated general control nonderepressible 2 (GCN2) protein kinase inhibitors reduce growth of leukemia cells” [Comput. Struct. Biotec... by Lea Lough, Dan Sherman, Manuel Becerra-Flores, Deepika Vasudevan, Olga Lavinda, Eric Ni, Hong Wang, Hyung Don Ryoo, Raoul Tibes, Timothy Cardozo
Published 2020-01-01
Article -
5
The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials by Mitesh J. Borad, Kelly K. Curtis, Hani M. Babiker, Martin Benjamin, Raoul Tibes, Ramesh K. Ramanathan, Karen Wright, Amylou C. Dueck, Gayle Jameson, Daniel D. Von Hoff
Published 2012-01-01
Article -
6
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms by Tariq I. Mughal, Alessandro M. Vannucchi, Simona Soverini, Alexandra Bazeos, Raoul Tibes, Giuseppe Saglio, Omar Abdel-Wahab, Animesh Pardanani, Rudiger Hehlmann, Tiziano Barbui, Richard Van Etten, Ayalew Tefferi, John M. Goldman
Published 2014-05-01
Article -
7
CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo by Leena Chaudhuri, Nicole D. Vincelette, Brian D. Koh, Ryan M. Naylor, Karen S. Flatten, Kevin L. Peterson, Amanda McNally, Ivana Gojo, Judith E. Karp, Ruben A Mesa, Lisa O. Sproat, James M. Bogenberger, Scott H. Kaufmann, Raoul Tibes
Published 2014-04-01
Article -
8
An International MDS/MPN Working Group’s perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative ne... by Tariq I. Mughal, Nicholas C.P. Cross, Eric Padron, Ramon V. Tiu, Michael Savona, Luca Malcovati, Raoul Tibes, Rami S. Komrokji, Jean-Jacques Kiladjian, Guillermo Garcia-Manero, Attilio Orazi, Ruben Mesa, Jaroslaw P. Maciejewski, Pierre Fenaux, Raphael Itzykson, Ghulam Mufti, Eric Solary, Alan F. List
Published 2015-09-01
Article -
9
P579: SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY by Pinkal Desai, Sagar Lonial, Amanda Cashen, Manali Kamdar, James S. Blachly, Ian W. Flinn, Susan O’brien, Jacqueline Garcia, Neha Korde, Javid Moslehi, Margaret Wey, Patricia Cheung, Shringi Sharma, Damilola Olabode, Hong Chen, Firasath Ali Syed, Mary Liu, Jamal Saeh, Raoul Tibes, Marcio Andrade, Tapan Kadia
Published 2023-08-01
Article -
10
P537: SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL by Giovanni Marconi, Shukaib Arslan, Shaun Fleming, Antonio Curti, James S Blachly, Giovanni Martinelli, Matteo Giovanni Della Porta, Ashish Bajel, Tim Sauer, Martina Crysandt, Arnaud Pigneux, Marina Konopleva, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Emily Rowe, Patricia Cheung, Ekaterina Jahn, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Nitin Jain
Published 2023-08-01
Article -
11
Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia by Andoni Garitano-Trojaola, Ana Sancho, Ralph Götz, Patrick Eiring, Susanne Walz, Hardikkumar Jetani, Jesus Gil-Pulido, Matteo Claudio Da Via, Eva Teufel, Nadine Rhodes, Larissa Haertle, Estibaliz Arellano-Viera, Raoul Tibes, Andreas Rosenwald, Leo Rasche, Michael Hudecek, Markus Sauer, Jürgen Groll, Hermann Einsele, Sabrina Kraus, Martin K. Kortüm
Published 2021-06-01
Article -
12
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemi... by Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris, Stephen A. Strickland, Jeffrey E. Lancet, Prithviraj Bose, M. Yair Levy, Raoul Tibes, Ivana Gojo, Christopher D. Gocke, Gary L. Rosner, Richard F. Little, John J. Wright, L. Austin Doyle, B. Douglas Smith, Judith E. Karp
Published 2015-09-01
Article -
13
The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes by Tamara K. Moyo, Jason H. Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Adam C. Seegmiller, Aaron T. Gerds, Gregory D. Ayers, Amy E. Dezern, Aziz Nazha, Peter Valent, Arjan A. van de Loosdrecht, Francesco Onida, Lisa Pleyer, Blanca Xicoy Cirici, Raoul Tibes, Klaus Geissler, Rami S. Komrokji, Jing Zhang, Ulrich Germing, David P. Steensma, Daniel H. Wiseman, Michael Pfeilstöecker, Chiara Elena, Nicholas C. P. Cross, Jean-Jacques Kiladjian, Michael Luebbert, Ruben A. Mesa, Guillermo Montalban-Bravo, Guillermo F. Sanz, Uwe Platzbecker, Mrinal M. Patnaik, Eric Padron, Valeria Santini, Pierre Fenaux, Michael R. Savona, On Behalf of the MDS/MPN International Working Group
Published 2022-09-01
Article